# Biovance Capital

> Biovance Capital is a VC fund in Lisbon backing Medical and Biotechnology. See 4 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Lisbon, Portugal
- Total investments: 4
- Last investment: Mar 2026
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/biovance
- Website: https://biovancecapital.com

Biovance Capital is a new € 51M fund to invest in early-stage biotech companies across Europe developing innovative therapeutics in all disease areas and drug modalities (small and large molecules, vaccines, cell, and gene therapies).

## Contacts

5 contacts available for Biovance Capital. Shizune tracks 2 team members at Biovance Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/biovance-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 50% |
| Biotechnology | 2 | 50% |
| Product Research | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 25% |
| Series A | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Portugal | 1 | 25% |
| The Netherlands | 1 | 25% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Joao Incio | General Partner | 2 | https://shizune.co/investors/profile/joao-incio |
| Ricardo Perdigão Henriques | Managing Partner | 3 | https://shizune.co/investors/profile/ricardo-perdig%C3%A3o-henriques |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Laigo Bio | Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders. | $6.4M | Seed | Mar 23, 2026 |  |
| Mondego Bio | Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile. |  | Series A | Sep 18, 2025 |  |
| Mondego Bio | Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile. |  | Series A | Sep 18, 2025 |  |
| Mondego Bio | Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile. |  | Series A | Sep 18, 2025 |  |

4 of 4 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 3 deals together
- [Torrey Pines Investment](https://shizune.co/investors/profile/torrey-pines-investment) — VC Fund, 3 deals together
- [Angelini Ventures](https://shizune.co/investors/profile/angelini-ventures) — VC Fund, 1 deal together
- [ARGOBIO](https://shizune.co/investors/profile/argobio) — VC Fund, 1 deal together
- [Cancer Research Horizons](https://shizune.co/investors/profile/cancer-research-technology) — VC Fund, 1 deal together
- [Curie Capital](https://shizune.co/investors/profile/curie-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Portugal Ventures](https://shizune.co/investors/profile/portugal-ventures) — VC Fund
- [Caixa Capital](https://shizune.co/investors/profile/caixa-capital-2) — VC Fund
- [Armilar Venture Partners](https://shizune.co/investors/profile/espirito-santo-ventures) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Portugal](https://shizune.co/investors/biotechnology-investors-portugal)
- [Biotech Investors in Portugal](https://shizune.co/investors/biotech-investors-portugal)
- [Medical Investors in Portugal](https://shizune.co/investors/medical-investors-portugal)
- [Medical VC Funds in Portugal](https://shizune.co/investors/medical-vc-funds-portugal)
- [Health Care VC Funds in Portugal](https://shizune.co/investors/health-care-vc-funds-portugal)
- [All VC Funds in Portugal](https://shizune.co/investors/vc-funds-portugal)

## FAQ

### What does Biovance Capital invest in?

Biovance Capital invests primarily in Medical, Biotechnology and Product Research startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in Portugal. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Biovance Capital?

Public channels for Biovance Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Biovance Capital?

The team at Biovance Capital includes Joao Incio (General Partner) and Ricardo Perdigão Henriques (Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co